In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Zimmer Biomet Holdings (ZBH), with a price target of $135. The company’s shares closed on Tuesday at $111.99.
Lichtman noted:
“During our recent time on the road with ZBH, CEO Bryan Hanson discussed near- and long-term priorities. Overall, his message suggests ZBH’s recovery remains on track—improvements in manufacturing supply, expected 2019 new product launches and management/personnel changes made during 2018 should put ZBH in position to go on offense during 2H19. Hanson noted that supply continues to improve and that salesforce confidence in supply consistency is growing. Management’s goal remains to sustainably deliver growth at or above ZBH’s weighted average market growth (WAMG) of 2-3% in 2020. In the interim, ZBH is putting in place initiatives to drive accelerated performance including new compensation plans, shifting the manufacturing focus from solely improving supply to cost-reduction and investing behind its higher growth markets to increase WAMG.”
According to TipRanks.com, Lichtman has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.9% and a 47.1% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Motus Gi Holdings Inc, and Integra Lifesciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zimmer Biomet Holdings with a $138.10 average price target, implying a 23.3% upside from current levels. In a report issued on November 26, SunTrust Robinson also reiterated a Buy rating on the stock with a $126 price target.
.
See today’s analyst top recommended stocks >>
Zimmer Biomet Holdings’ market cap is currently $22.85B and has a P/E ratio of 12.87. The company has a Price to Book ratio of 1.87.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products, sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. The company operates through three geographical segments: America, Europe and Asia Pacific.
